Singapore markets closed

PFE Dec 2025 27.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
4.00000.0000 (0.00%)
As of 11:48AM EDT. Market open.
Full screen
Previous close4.0000
Expiry date2025-12-19
Day's range4.0000 - 4.2000
Contract rangeN/A
Open interest5.49k
  • Benzinga

    GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims

    GSK Plc (NYSE:GSK) has been reportedly sued by an independent Connecticut laboratory, Valisure, accusing the pharmaceutical giant of defrauding the U.S. government and taxpayers by concealing cancer risks associated with Zantac, once a blockbuster heartburn drug. Related: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac. In a whistleblower complaint filed on Monday, Valisure claimed GSK violated the federal False Claims Act by hid

  • Benzinga

    Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute

    A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in damages, concluding that AstraZeneca’s blockbuster lung cancer drug, Tagrisso, infringed on Pfizer’s Wyeth unit’s patent rights. The jury found that AstraZeneca’s Tagrisso violated two patents held by Pfizer, which cover methods for treating cancer using the breast cancer drug Nerlynx. Also Read: Double Good News For AstraZeneca’s Breast Cancer Drugs. Puma Biotechnology Inc (


    Moderna and Novavax Hope for Early Launch of This Year’s Covid-19 Shots, Despite FDA Delay

    After disappointing sales for their Covid vaccines last year, drugmakers are hoping for an August rollout of the updated shot.